Gloria A. Salazar

Gloria A. Salazar

Auto-generated profile, based on publicly available information

Gloria A. Salazar

McGovern Medical School The University of Texas Health Science Center at Houston

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 June 2017 in Arthritis & Rheumatology
Verified
Journal Article
Closed access
PDF file
MWMinghua Wu
Minghua Wu
MBMurray Baron
Murray Baron
CPClaudia Pedroza
Claudia Pedroza
GSGloria A. Salazar
Gloria A. Salazar
JYJun Ying
Jun Ying
SAShervin Assassi
Shervin Assassi

20 January 2022 in ACR Open Rheumatology
Verified
Journal Article
Open access
PDF file
BJBochra Jandali
Bochra Jandali
GSGloria A. Salazar
Gloria A. Salazar
MHMarie Hudson
Marie Hudson
MFMarvin Jacob Fritzler
Marvin Jacob Fritzler
MLMarka A. Lyons
Marka A. Lyons
SAShervin Assassi
Shervin Assassi
Objective: The objective of this study was to assess the predictive significance of anti‐Scl‐70 (anti‐topoisomerase I) antibodies, as determined by three different methods, for decline in forced vital capacity (FVC) within the first year of follow‐up in patients with systemic sclerosis (SSc)‐related interstitial lung disease (ILD).Methods: Patients in the Genetics Versus Environment in Scleroderma Outcome Study cohort who had ILD (verified by imaging) and available FVC% at enrollment, plus 12 to 18 months thereafter, were examined. All patients had a disease duration of 5 years or less at enrollment. The annualized percentage change in FVC% at 1 year follow‐up was the outcome variable. Anti‐Scl‐70 antibodies were determined by passive immunodiffusion (ID) against calf thymus extract, chemiluminescent immunoassay (CIA), and line blot immunoassay (LIA).Results: Ninety‐one patients with a mean disease duration of 2.36 years were included. Anti‐Scl‐70 antibodies by ID predicted a faster rate of FVC% decline (b = −0.06, P = 0.04). None of the other clinical or serological variables significantly predicted ILD progression. Interestingly, anti‐Scl‐70 antibodies as determined by CIA and LIA were not significant predictors of FVC decline (P = 0.26 and 0.64, respectively). The observed level of agreement between ID and LIA was moderate (κ = 0.568), whereas it was good between ID and CIA (κ = 0.66).Conclusion: Anti‐Scl‐70 antibodies determined by ID predicted faster FVC decline in patients with SSc‐related ILD. Notably, both CIA and LIA for the same antibody did not predict rate of FVC decline at their current cutoffs of positivity. The discrepancy observed between anti‐Scl‐70 antibody assays can have relevant implications for clinical care and trial enrichment strategies in SSc‐ILD.

1 April 2021 in Chest
Verified
Journal Article
Open access
PDF file
JRJulio Rodarte
Julio Rodarte
BABobak Akhavan
Bobak Akhavan
GSGloria A. Salazar
Gloria A. Salazar
SCSujith V Cherian
Sujith V Cherian
RMRosa M. Estrada-Y- Martin
Rosa M. Estrada-Y- Martin
Clinical Presentation A 52-year-old man presented with hemoptysis of 2 weeks’ duration. He had been experiencing hoarseness, right-sided pleuritic chest pain, subjective fevers, chills, night sweats, and 10 pounds weight loss for the previous 2 months. He additionally reported severe frontal headaches, nasal congestion, and intermittent epistaxis, which had been present for a year before his current presentation. He had worked in construction and denied tobacco or illicit drug use.